$2000 ReportJust scanning the syllabus and notes to it. We are in with some prettty big names here.
Primary Sclerosing Cholangitis - Pipeline Review, H1 2018
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H1 2018, provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape.
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
Keyplayers in Primary Sclerosing Cholangitis - Pipeline Review, H1 2018
Acorda Therapeutics Inc
Albireo Pharma Inc
Allergan Plc
Conatus Pharmaceuticals Inc
Dr. Falk Pharma GmbH
DURECT Corp
Gilead Sciences Inc
iCo Therapeutics Inc.
Intercept Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Noxopharm Ltd
Sancilio & Company Inc
Seres Therapeutics Inc
Shenzhen HighTide Biopharmaceutical Ltd
Shire Plc
Sirnaomics Inc